rab5a基因在肿瘤转移中的作用研究

为研究rab5a基因在肿瘤转移机制中的作用,将该基因稳定转染至低转移肺腺癌细胞系AGZY83-a中,采用Superarray肿瘤转移相关基因微芯片分析rab5a对肿瘤转移相关基因的表达影响,共获得了5个差异表达基因,rab5a基因促进s100a4的表达,同时抑制了nm23a、rac1、cst3、col4a2等基因的表达,并分别在RNA及蛋白水平进行验证,确认rab5a基因影响了肿瘤转移的多个途径,促进了肿瘤细胞转移能力增强。     

一个与非小细胞肺癌转移相关的基因--RAB5A基因

采用mRNA差异展示技术(mRNA DD)研究具有相同细胞来源,但转移能力高低不同的人肺腺癌细胞系AGZY83-a(低转移)和Anip973(高转移),分析在两个细胞系中基因差异表达的情况,发现在高转移细胞系中有RAB5A基因的表达.该基因为蛋白质入胞信号的调控者,为RAS超家族成员.为进一步证实其转录表达的调控改变情况,以及RAB5A高表达的临床意义,进一步采用RT-PCR和免疫组织化学的方法检测了50例临床非小细胞肺癌的手术标本,结果表明,RAB5A的表达有随转移发生而增强的趋势,而RAB5A的蛋白表达程度在有转移的病例中明显增强(P<0.05).     

一个与非小细胞肺癌转移相关的基因――RAB5A基因

采用mRNA差异展示技术（mRNA DD）研究具有相同细胞来源,但转移能力高低不同的人肺腺癌细胞系AGZY83-a（低转移）和Anip973(高转移),分析在两个细胞系中基因差异表达的情况,发现在高转移细胞系中有RAB5A基因的表达。该基因为蛋白质入胞信号的调控者,为RAS超家族成员。为进一步证实其转录表达的调控改变情况,以及RAB5A高表达的临床意义,进一步采用RT-PCR和免疫组织化学的方法检测了50例临床非小细胞肺癌的手术标本,结果表明,RAB5A的表达有随转移发生而增强的趋势,而RAB5A的蛋白表达程度在有转移的病例中明显增强(P<0.05)。 Abstract：　Using mRNA differential display (mRNA DD)techniques, we analyzed the differences of gene expression between two human lung adenocarcinoma cell lines,AGZY83-a and Anip973. Anip973 was isolated from AGZY83-a, but manifested much higher metastatic potential than the parent line. The results showed that there were significant differences on gene expression between the two cell lines and that there was over-expression of RAB5Agene in the Anip973 cell line. The product of RAB5Agene was recognized as signal regulators of endocytotic pathway and protein trafficking at the cell surface, and belong to a member of the RAS superfamily. Furthemore, we compared to the expression of RAB5Agene and RAB5Aprotein in clinical samples of 50 cases non-small lung carcinoma and nearby lymph node by means of RT-PCR and immunohistochemistry method. The results indicated that the high expression of RAB5Ain metastatic tumor and the enhancement level of RAB5Ain metastatic tumor and the enhancement level of expression were corresponded with the increase of metastatic degree. And there were significance of difference on the expression degree of RAB5Aprotein between non-small lung carcinoma with metastasis and non- metastasis (P<0.05).     

野生型P53、P16基因协同对肺腺癌细胞系生长抑制作用的研究

为了探讨野生型P53基因及P16基因在恶性肿瘤基因治疗中的作用,用腺病毒为载体将野生型P53基因转入高、低转移的肺腺癌细胞系Anip973、AGZY83-a和经野生型P16基因质粒转染的高、低转移肺腺癌细胞系Anip973（Anip973P16）、AGZY83-a（AGZY83-aP16）。对各组转染细胞进行生长曲线、MTT生长抑制率、原位末端标记、Western-blotting等技术检测分析。结果发现（1）野生型P53蛋白的过表达对上述肺腺癌细胞系均呈现出较强的生长抑制作用。（2）野生型P53蛋白的过表达对高转移肺癌细胞系Anip973的抑制作用明显高于低转移细胞系AGZY83-a。（3）野生型p53蛋白的过表达对经野生型P16基因转染的高、低转移的肺癌细胞Anip973、AGZY83-a抑制作用明显高于未经P16基因转染的细胞。野生型P53基因可以作为肺腺癌基因治疗的候选基因。肿瘤抑制基因P53、P16的联合转染可能是对肺腺癌进行基因治疗的有效手段。 Abstract：To investigate the suppression effect of tumor suppressor genes in lung adenocarcinoma cell lines,we transferred a pair of lung adenocarcinoma cell lines with different metastasis potential,Anip973(High-metastasis potential cell line) and AGZY83-a (Low-metastasis potential cell line)and this pair of cell lines transfected with P16 gene:AGZY83-a P16 and Anip973 P16 with wild type P53 gene with adenovirus vector.The suppression effects of P53 gene were evaluated by cell growth curve,MTT,western-blotting analysis and TUNEL technique.Overexpression of wild-type P53 gene in AGZY83-a,Anip973,Anip973 P16 and AGZY83-a P16 inhibited the growth of these four kinds of lung cancer cells and induced apoptosis of the cells.The suppression effect of P53 gene in Anip973 and Anip973 P16 was higher than AGZY83-a and AGZY83-a P16 while co-expression of P53 and　P16 in this pair of cell lines inhibited the cells more efficiently comparing with the expression of P53 alone.Wild-type P53 gene might act as a candidate gene in lung adenocarcinoma gene therapy while co-transfection of P53 and P16 genes was a more effective method.     

S100A4基因在结肠癌中的表达及意义

目的：通过检测S100A4基因在结肠癌细胞系及结肠癌组织中的表达,探讨其与结肠癌的关系。方法：运用RT-PCR法检测不同结肠癌细胞系中S100A4基因的表达情况;通过原位杂交和免疫组化方法检测61例结肠癌标本中S100A4基因的表达。结果：结肠癌细胞系Lovo及HT29均有S100A4基因表达。S100A4蛋白和RNA在结肠癌中表达率分别为36．1％和34.4％,而在正常结肠组织中不表达（p〈0．05）。临床分期晚比临床分期早的患者S100A4表达明显增高（p〈0.05）;有淋巴结转移的患者比无淋巴结转移的患者S100A4表达明显增高（p〈0．05）。此外,S100A4表达还与肿瘤大小,病理学分级,肉眼分型等相关。结论：结肠癌中S100A4基因表达增高,而且与肿瘤的侵袭及转移密切相关,是判断结肠癌生物学行为及预后的有价值的指标。     

低氧模拟剂氯化钴对胃癌细胞BGC823中S100A4基因表达的影响

摘要: S100A4基因是肿瘤侵袭转移相关的重要基因, 该基因高表达与胃癌浸润、淋巴结转移及胃癌细胞体外侵袭力密切相关。为探讨S100A4基因高表达的机制, 文章应用低氧模拟剂氯化钴处理胃癌细胞BGC823, RT-PCR、免疫组化、免疫荧光及Western blotting方法分别检测BGC823细胞中S100A4 mRNA及蛋白表达情况。结果显示, 氯化钴处理胃癌BGC823细胞后, S100A4 mRNA及蛋白表达明显增加。提示低氧模拟剂氯化钴可促进胃癌细胞BGC823中S100A4 基因表达。     

S100A4基因表达在肿瘤转移中的作用

肿瘤转移是细胞恶性的重要标志之一,有许多基因和因子都参与这一过程。对S100A4基因的研究发现,它可参与细胞周期调控、细胞增殖与分化、血管生成、细胞外基质重建等多种生命过程,调控细胞的生长和运动。在某些特定的肿瘤细胞内,它的表达含量的增加可促进肿瘤细胞发生转移,并与癌症的发生具有某些相关性,可能对人类癌症的发生具有预后作用。现就S100A4基因表达与肿瘤转移的关系进行初步的探讨,以期对癌症的临床诊断提供一些参考。     

nm23-H1基因转染L9981肺癌细胞前后基因表达谱的变化

应用基因芯片检测L9981细胞转染nm23-H1基因前后细胞基因表达谱的改变.提取L9981细胞转染nm23-H1基因前后细胞的总RNA,纯化为mRNA后再转录为cDNA.cDNA经限制性内切酶Sau3AI消化后,cDNA片段分别用cy3和cy5标记,与定制的包含14000个基因芯片杂交.杂交结果经扫描和软件分析,nm23-H1基因转染L9981细胞后发现1156(8.26%,1156/14000)个基因表达上调,而642(4.59%,642/14000)个基因表达下调.涉及基因包括信号传导、癌基因与抑癌基因、转移相关基因、细胞周期与凋亡、细胞外基质与细胞骨架相关基因,以及细胞因子和转录因子等.nm23-H1基因是通过对转移相关基因的调节来发挥其抑制肺癌细胞株L9981侵袭和转移作用的.     

利用Pyrobest DNA聚合酶一步法进行大片段基因的定点突变

目的:介绍一种简单、快速、高效和经济的进行大片段基因定点突变的方法。方法:小量抽提含有NM23H1-EGFP融合基因的逆转录病毒真核表达质粒pLXSN-NM23H1-EGFP,体外合成突变引物对,利用高保真Pyrobest DNA聚合酶对质粒DNA进行PCR突变反应,然后用DpnⅠ限制性内切酶消化PCR产物以去除模板DNA,取适量消化产物转化大肠杆菌XL1-Blue,随机挑选克隆进行测序筛选、鉴定所需突变株。结果:在NM23H1-EGFP基因中引入了S44A、P96S、H118F、S120G、P96S-S120G等5个替换突变位点及9bp处的插入突变。结论:该方法简单、快速、高效、经济,不须纯化中间产物,不须亚克隆,突变效率几乎为100%,是一种值得推广应用的方法。     

高低转移肺腺癌细胞系Anip973和AGZY83-a中P21过表达的研究

为探讨肿瘤抑制基因对肺腺癌细胞生长的抑制作用,利用FuGene转染方法将 P21基因的表达质粒转入一对分别具高、低转移能力的肺腺癌细胞系An ip973和AGZY83-a中。对p21蛋白过表达的细胞系进行了细胞生长曲线,克隆形成率,原位末端标记分析和流式细胞仪分析。p21蛋白过表达的一对细胞系细胞生长曲线斜率降低,克隆形成能力下降并出现明显的G1期阻滞,但未检测到凋亡信号。结果表明p21基因的过表达通过G1期阻滞抑制这一对肺腺癌细胞的生长,P21基因可以作为肺腺癌基因治疗的候选基因。 Abstract:In order to investigate the suppression effect of tumor suppressor genes in lung adenocarcinoma,we transfected P21 expression vector into a pair of lung adenocarcinoma cell lines with different metastasis potential:Anip973(high metastasis potential)and AGZY83-a(low metastasis potential).The suppression effects of p21 were evaluated by cell growth curve,cloning efficiency assay,flow cytometric analysis and Tunel technique.We found that increased expression of p21 in both cell lines was associated with significant lengthening of G1 phase,decreased proliferation potential and decreased cloning efficiency.No apoptosis was found in the cell lines with overexpressed P21 gene.The results showed that increased expression of P21 gene suppressed the lung adenocarcinoma cells by G1 arrest and P21 gene proved a candidate gene in lung adenocarcinoma gene therapy.     

Anticancer activity of tirucallane triterpenoids from Amoora dasyclada

A new tetranortriterpene 3alpha-acetoxy-24,25,26,27-tetranortirucalla-7-ene-23(21)-lactone (3), and eleven other compounds were isolated from the twigs of Amoora dasyclada. The structure of compound 3 was identified on the basis of spectroscopic data, and the bioactive experiments of 1 and 3-5 against AGZY 83-a (human lung cancer cells) and SMMC-7721 (human liver cancer cells) are documented. Among them, compound 5 exhibited a strong activity against SMMC-7721.     

Upregulation of BNIP3 promotes apoptosis of lung cancer cells that were induced by p53

It has been shown that p53 induces cell apoptosis and the Bcl-2 family plays key roles in this process. However, the molecular mechanism of p53 apoptotic pathway is still unclear. Here, we show that overexpression of exogenous wild-type p53 induced apoptosis in lung cancer cells and high metastasis potential cells had a faster rate of apoptosis than low metastasis potential cells. The expression of pro-apoptotic gene BNIP3 was increased significantly both in Anip973 and 95D cell lines which have high metastasis ability, but not AGZY83-a or little increased in 95C cell lines which possess low metastasis ability. Overexpression of BNIP3 increases apoptotic rate induced by p53 in AGZY83-a cells. Blocking the expression of BNIP3 by siRNA in Anip973 cells decreased apoptotic rate mediated by p53. Taken together, these data suggest that high level expression of BNIP3 mediated rapid apoptosis that was triggered by p53 in lung cancer cells.     

NM23-H1 tumor suppressor physically interacts with serine-threonine kinase receptor-associated protein, a transforming growth factor-beta (TGF-beta) receptor-interacting protein, and negatively regulates TGF-beta signaling

NM23-H1 is a member of the NM23/NDP kinase gene family and a putative metastasis suppressor. Previously, a screen for NM23-H1-interacting proteins that could potentially modulate its activity identified serine-threonine kinase receptor-associated protein (STRAP), a transforming growth factor (TGF)-beta receptor-interacting protein. Through the use of cysteine to serine amino acid substitution mutants of NM23-H1 (C4S, C109S, and C145S) and STRAP (C152S, C270S, and C152S/C270S), we demonstrated that the association between these two proteins is dependent on Cys(145) of NM23-H1 and Cys(152) and Cys(270) of STRAP but did not appear to involve Cys(4) and Cys(109) of NM23-H1, suggesting that a disulfide linkage involving Cys(145) of NM23-H1 and Cys(152) or Cys(270) of STRAP mediates complex formation. The interaction was dependent on the presence of dithiothreitol or beta-mercaptoethanol but not H(2)O(2). Ectopic expression of wild-type NM23-H1, but not NM23-H1(C145S), negatively regulated TGF-beta signaling in a dose-dependent manner, enhanced stable association between the TGF-beta receptor and Smad7, and prevented nuclear translocation of Smad3. Similarly, wild-type NM23-H1 inhibited TGF-beta-induced apoptosis and growth inhibition, whereas NM23-H1(C145S) had no effect. Knockdown of NM23-H1 by small interfering RNA stimulated TGF-beta signaling. Coexpression of wild-type STRAP, but not STRAP(C152S/C270S), significantly stimulated NM23-H1-induced growth of HaCaT cells. These results suggest that the direct interaction of NM23-H1 and STRAP is important for the regulation of TGF-beta-dependent biological activity as well as NM23-H1 activity.     

Wild-type NM23-H1, but not its S120 mutants, suppresses desensitization of muscarinic potassium current

NM23 (NDP kinase) modulates the gating of muscarinic K+ channels by agonists through a mechanism distinct from GTP regeneration. To better define the function of NM23 in this pathway and to identify sites in NM23 that are important for its role in muscarinic K+ channel function, we utilized MDA-MB-435 human breast carcinoma cells that express low levels of NM23-H1. M2 muscarinic receptors and GIRK1/GIRK4 channel subunits were co-expressed in cells stably transfected with vector only (control), wild-type NM23-H1, or several NM23-H1 mutants. Lysates from all cell lines tested exhibit comparable nucleoside diphosphate (NDP) kinase activity. Whole cell patch clamp recordings revealed a substantial reduction of the acute desensitization of muscarinic K+ currents in cells overexpressing NM23-H1. The mutants NM23-H1P96S and NM23-H1S44A resembled wild-type NM23-H1 in their ability to reduce desensitization. In contrast, mutants NM23-H1S120G and NM23-H1S120A completely abolished the effect of NM23-H1 on desensitization of muscarinic K+ currents. Furthermore, NM23-H1S120G potentiated acute desensitization, indicating that this mutant retains the ability to interact with the muscarinic pathway, but has properties antithetical to those of the wild-type protein. We conclude that NM23 acts as a suppressor of the processes leading to the desensitization of muscarinic K+ currents, and that Ser-120 is essential for its actions.     

Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression

Breast cancer is a common cancer in women, with a highly variable course, from inoffensive to lethal. To find a more effective strategy for its treatment, sodium valproate has been tested as an anti-cancer drug; it is the only clinically available histone deacetylase inhibitor. However, data about the effects of sodium valproate on breast cancer are insufficient in both animals and humans; studies have yielded conflicting conclusions. In particular, little is known about the association between expression of the metastasis suppressor Nm23H1 gene and breast cancer. We hypothesized that sodium valproate regulates NM23H1 expression, and affects migration and/or invasion. We found that sodium valproate at concentrations of 0.8-3.2 mM inhibits migration and modulates Nm23H1 gene expression in a concentration-dependent manner. Confluent MDA-MB-231 cells were scratched by a micropipette tip after VPA treatment for 24 h; 24 h later, the scratch was almostly closed in the 0 mM VPA-treated cells, while the 3.2 mM VPA-treated cells migrated the slowest. The cell migration ratio exposed to 0.8, 1.6 and 3.2 mM VPA was about 66.67, 30.67 and 26.67% (P < 0.05). We also found evidence that sodium valproate upregulates NM23H1 expression, which is a clue to its anti-cancer mode of action. The NM23H1 gene expression was relative fold increased determined by Western blotting at 3.2 mM VPA. Collectively, these observations indicate that sodium valproate has potential for use in breast cancer treatment.